December 17, 2018 07:42 AM EST

Broadening its oncology focus, Innovent adds three Incyte drugs to portfolio for $40M cash

Amber Tong

Buoyed by promising Phase III data on its PD-1 partnered with Eli Lilly $LLY, Innovent Biologics is making another appearance on the global dealmaking …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Broadening its oncology focus, Innovent adds three Incyte drugs to portfolio for $40M cash

Amber Tong

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps

ARCH, F-Prime and Mubadala pump $200M into former Denali programs

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Sana’s stock soars on new cell therapy data; UniQure’s $75M offering

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line

Broad­en­ing its on­col­o­gy fo­cus, In­novent adds three In­cyte drugs to port­fo­lio for $40M cash

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Broadening its oncology focus, Innovent adds three Incyte drugs to portfolio for $40M cash